Abstract
The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study was performed to investigate the relationship between blood pressure (BP) and development of stroke or myocardial infarction (MI) in Japanese hypertensive patients. A total of 26,512 hypertensive patients (mean age: 62.2 years, 43.9% men) were analyzed. All patients received open-labelled losartan for a maximum of 5 years. Endpoints were stroke, MI including sudden cardiac death, and all cardiovascular (CV) events (stroke and MI). The mean observation period was 3.0 years. The mean baseline systolic/diastolic BP was 165.8/94.8 mmHg and decreased to 141.6/82.0 mmHg during treatment. The incidences of stroke, MI, and total CV events were 3.90, 1.02, and 4.92 per 1,000 patient-years, respectively. Aging, diabetes, a history of CV disease, and smoking were independent risk factors for CV events. The risk of all CV events was positively related to BP level during treatment, and increased significantly when the BP exceeded 140/90 mmHg. Age was a strong contributor to CV events, but about a half of the very elderly patients (≥85 years, n=692) had a BP below 140/90 mmHg during treatment and significantly fewer events occurred in these patients than in those with a BP of 140/90 mmHg or higher. These results suggest that BP should be below 140/90 mmHg in Japanese patients with hypertension for reducing the risk of CV events. BP was controlled below 140/90 mmHg in a half of the very elderly hypertensive patients in this study, and these patients also had a lower incidence of CV events.
Similar content being viewed by others
Article PDF
References
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997.
Dahlof B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
Neal B, MacMahon S, Chapman N, Blood Pressure Lowering Treatment Trialists' Collaboration : Effects of ACE inhibitors, calcium antagonists, and other blood-pressure–lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955–1964.
Staessen JA, Wang JG, Thijs L : Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305–1315.
Japanese Society of Hypertension : Guidelines for the management of hypertension (JSH 2004). Hypertens Res 2006; 29 ( Suppl): S1–S105.
Chobanian AV, Bakris GL, Black HR, et al: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.
Naritomi H, Fujita T, Ito S, et al: Design and baseline characteristics of a cohort study in Japanese patients with hypertension: Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH). Hypertens Res 2007; 30: 807–814.
Naritomi H, Fujita T, Ito S, et al: Efficacy and safety of long-term losartan therapy demonstrated by a cohort study in Japanese patients with hypertension: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) Study. Hypertens Res 2008; 31: 295–304.
Black HR, Elliott WJ, Grandits G, et al: Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289: 2073–2082.
Tanizaki Y, Kiyohara Y, Kato I, et al: Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. Stroke 2000; 31: 2616–2622.
Matsuzaki M, Kita T, Mabuchi H, et al: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 2002; 66: 1087–1095.
Ueda K, Omae T, Hasuo Y, et al: Prognosis and outcome of elderly hypertensives in a Japanese community: results from a long-term prospective study. J Hypertens 1988; 6: 991–997.
Hansson L, Zanchetti A, Carruthers SG, et al, HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762.
Shimamoto K, Kita T, Mabuchi H, et al: Effects of hypertension and type 2 diabetes mellitus on the risk of total cardiovascular events in Japanese patients with hypercholesterolemia: Implications from the Japan Lipid Intervention Trial (J-LIT). Hypertens Res 2007; 30: 119–123.
American Diabetes Association : Treatment of hypertension in adults with diabetes. Diabetes Care 2002; 25: 199–201.
Guidelines Committee : 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.
Lewington S, Clarke R, Qizilbash N, Pete R, Collins R, Prospective Studies Collaboration : Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.
Goldstein LB, Adams R, Becker K, et al: Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2001; 103: 163–182.
Ferrucci L, Furberg CD, Penninx BWJH, et al: Treatment of isolated systolic hypertension is most effective in older patients with high-risk profile. Circulation 2001; 104: 1923–1926.
Amery A, Birkenhäger W, Brixko P, et al: Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1 ( 8442): 1349–1354.
Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO : Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–1285.
Heikinheimo RJ, Haavisto MV, Kaarela RH, Kanto AJ, Koivunen MJ, Rajala SA : Blood pressure in the very old. J Hypertens 1990; 8: 361–367.
Kjeldsen SE, Dahlof B, Devereux RB, et al: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491–1498.
August P : Initial treatment of hypertension. N Engl J Med 2003; 348: 610–617.
Arima H, Tanizaki Y, Kiyohara Y, et al: Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: the Hisayama study. Arch Intern Med 2003; 163: 361–366.
Perry HM Jr, Davis BR, Price TR, et al: Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000; 284: 465–471.
Bulpitt C, Fletcher A, Beckett N, et al: Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging 2001; 18: 151–164.
Bulpitt CJ, Beckett NS, Cooke J, et al: Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21: 2409–2417.
JATOS Study Group: The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS): protocol, patient characteristics, and blood pressure during the first 12 months. Hypertens Res 2005; 28: 513–520.
Ogihara T, Saruta T, Matsuoka H, et al: Valsartan in Elderly Isolated Systolic Hypertension (VALISH) study: rationale and design. Hypertens Res 2004; 27: 657–661.
Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP, The INDANA Project Steering Committee : J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med 2002; 136: 438–448.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shimamoto, K., Fujita, T., Ito, S. et al. Impact of Blood Pressure Control on Cardiovascular Events in 26,512 Japanese Hypertensive Patients: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) Study, a Prospective Nationwide Observational Study. Hypertens Res 31, 469–478 (2008). https://doi.org/10.1291/hypres.31.469
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.469
Keywords
This article is cited by
-
Laparoscopic adrenalectomy vs. radiofrequency ablation for the treatment of primary aldosteronism. A single center retrospective cohort analysis adjusted with propensity score
Surgical Endoscopy (2022)
-
Systolic hypertension: an increasing clinical challenge in Asia
Hypertension Research (2015)
-
Chapter 3. Principles of treatment
Hypertension Research (2014)
-
The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID)
Hypertension Research (2013)
-
Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST Study
Hypertension Research (2013)